Blood flow and Vd (water): both biomarkers required for interpreting the effects of vascular targeting agents on tumor and normal tissue.
AffiliationAcademic Department of Radiation Oncology, The University of Manchester, Manchester, UK.
MetadataShow full item record
AbstractPositron emission tomography studies with oxygen-15-labeled water provide in vivo quantitative tissue perfusion variables-blood flow and fractional volume of distribution of water [V(d) (water)]. To investigate the relationship between perfusion variables and the effect of vascular-targeting agents on vasculature, we measured tissue perfusion in tumors, spleen, kidney, and liver before and after treatment with combretastatin-A4-phosphate, a combination of nicotinamide and carbogen (N/C), and interferon (IFN). We observed that mean tumor blood flow and V(d) (water) was lower than in kidney, liver, and spleen at baseline. Blood flow and V(d) (water) were related in tumor (r = 0.62; P = 0.004) at baseline, but not in other normal tissues evaluated, where minimal variations in V(d) (water) were observed over a wide range of blood flow. Despite the relationship between blood flow and V(d) (water) in tumors before intervention, vascular-targeting agent-induced changes in these perfusion variables were not correlated. In contrast, changes in blood flow and V(d) (water) correlated in kidney and spleen after N/C and in kidney after combretastatin-A4-phosphate. The close relation between blood flow and V(d) (water) in tumors but not normal tissue may reflect barriers to fluid exchange in tumors because of necrosis and/or increased interstitial fluid pressure and underlies the importance and interdependence of these positron emission tomography perfusion variables under these conditions. As blood flow and V(d) (water) signify different aspects of tissue perfusion, the differential effects of interventions on both variables, flow and V(d) (water), should therefore be reported in future studies.
CitationBlood flow and Vd (water): both biomarkers required for interpreting the effects of vascular targeting agents on tumor and normal tissue. 2009, 8 (2):303-9 Mol. Cancer Ther.
JournalMolecular Cancer Therapeutics
- Combretastatin A-4 phosphate as a tumor vascular-targeting agent: early effects in tumors and normal tissues.
- Authors: Tozer GM, Prise VE, Wilson J, Locke RJ, Vojnovic B, Stratford MR, Dennis MF, Chaplin DJ
- Issue date: 1999 Apr 1
- Human tumor blood flow is enhanced by nicotinamide and carbogen breathing.
- Authors: Powell ME, Hill SA, Saunders MI, Hoskin PJ, Chaplin DJ
- Issue date: 1997 Dec 1
- Preferential action of arsenic trioxide in solid-tumor microenvironment enhances radiation therapy.
- Authors: Griffin RJ, Williams BW, Park HJ, Song CW
- Issue date: 2005 Apr 1
- Assessment of inter- and intrapatient variability in C15O2 positron emission tomography measurements of blood flow in patients with intra-abdominal cancers.
- Authors: Wells P, Jones T, Price P
- Issue date: 2003 Dec 15
- Measurements of blood flow and exchanging water space in breast tumors using positron emission tomography: a rapid and noninvasive dynamic method.
- Authors: Wilson CB, Lammertsma AA, McKenzie CG, Sikora K, Jones T
- Issue date: 1992 Mar 15